Células madres estromales como Terapia Innovadora en el tratamiento de displasia broncopulmonar neonatal: revisión bibliográfica
Palabras clave:
Displasia broncopulmonar, Células madre estromales, neonatos, prematuros extremosResumen
La displasia broncopulmonar (DBP) es una enfermedad pulmonar crónica que afecta a neonatos, especialmente en aquellos con peso extremadamente bajo al nacer. Esta revisión explora el potencial de las células madre estromales (CME) en el tratamiento de la DBP, analizando estudios preclínicos y clínicos que destacan su eficacia y mecanismos de acción. Se realizó una revisión bibliográfica en bases de datos científicas como Proquest, Scopus, Springer, Web of Science, Google Scholar, seleccionando estudios entre 2018 y 2024. Se incluyeron investigaciones preclínicas y clínicas sobre el uso de células madre estromales para el tratamiento de la displasia broncopulmonar. Los resultados muestran que los pacientes que más se benefician del tratamiento con células madre mesenquimatosas (MSCs) para la displasia broncopulmonar (BPD) son principalmente los recién nacidos extremadamente prematuros, la administración temprana muestra resultados más favorables. Se concluye que aunque se han mostrado múltiples beneficios en los ensayos con animales aún hacen falta más estudios clínicos con el fin de optimizar los protocolos de tratamiento, especialmente en cuanto a la dosis y la elección de la vía de administración.
Descargas
Citas
Ahn, S. Y., Chang, Y. S., Lee, M. H., Sung, S.I., Lee, B.S., Kim, K.S., Kim, A.R. & Park, W.S. (2021). Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial. Stem Cells Translational Medicine, 10(8), 1129-1137. https://doi.org/10.1002/sctm.20-0330
Ai, D., Shen, J., Sun, J., Zhu, Z., Gao, R., Du, Y., Yuan, L., Chen, C. & Zhou, J. (2022). Mesenchymal stem cell-derived extracellular vesicles suppress hyperoxia-induced transdifferentiation of rat alveolar type 2 epithelial cells. Stem Cells and Development, 31(3-4), 53-66. https://doi.org/10.1089/scd.2021.0256
Albertine, K.H., Rebentisch, A., Dawson, E., Boerum, J.V., Major, E., Štipka, J., Foreman, H., Headden, D., Vordos, Z., Beck, E., Wang, Z., Yang, H., Yu, B., Dahl, M.J., Null, D.M., Bizzotto, D., Veneroni, C., Lavizzari, A., Dellacà, R.L., Delavogia, E., Mitsialis, S.A., &
Kourembanas, S. (2024). Mesenchymal Stromal Cell Extracellular Vesicles Improve Lung Development in Mechanically Ventilated Preterm Lambs. American Journal of Physiology. Lung Cellular and Molecular Physiology, 326(6). L770-L785. https://doi.org/10.1152/ajplung.00349.2023
Bonadies, L., Zaramella, P., Porzionato, A., Perilongo, G., Muraca, M., Baraldi, E. (2020). Present and Future of Bronchopulmonary Dysplasia. Journal of Clinical Medicine, 9(5), 15-39. https://doi.org/10.3390/jcm9051539 .
Braun, R. K., Chetty, C., Balasubramaniam, V., Centanni, R., Haraldsdottir, K., Hematti, P. & Eldridge, M.W. (2018). Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochemical and Biophysical Research Communications, 503(4), 2653-2658. https://doi.org/10.1016/j.bbrc.2018.08.019
Cerro Marín, M. J., Ormazábal, I. G., Gimeno-Navarro, A., Álvarez-Fuente, M., López-Ortego, P., Ávila-Álvarez, A., Arruza Gómez, L., González-Menchen, C., Labrandero de Lera, C., Lozano Balseiro, M., Moreno Gutiérrez, L., Melen Frajilich, G., Ramírez Orellana, M., Saldana García, N.,
Pavon Delgado, A., Vento Torres, M. (2024). Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: Results of a phase 1 clinical trial with 2-year follow-up. Cytotherapy, 26(6), 632-640. https://doi.org/10.1016/j.jcyt.2024.02.028
Collins, A. (2020). Stem-cell therapy for bronchopulmonary dysplasia. Current Opinion in Pediatrics, 32(2), 210-215. https://doi.org/10.1097/MOP.0000000000000862
Costela-Ruiz, V. J., Melguizo-Rodríguez, L., Bellotti, C., Illescas-Montes, R., Stanco, D., Renata Arciola, C. & Lucarelli, E. (2022). Different sources of mesenchymal stem cells for tissue regeneration: A guide to identifying the most favorable one in orthopedics and dentistry applications. International Journal of Molecular Sciences, 23(11), 6356. https://doi.org/10.3390/ijms23116356
Dabrowska, S., Andrzejewska, A., Janowski, M. & Lukomska, B. (2020). Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: Therapeutic outlook for inflammatory and degenerative diseases. Frontiers in Immunology, 11, 591065. https://doi.org/10.3389/fimmu.2020.591065
El-Sayed, M., El-Feky, M. A., El-Amir, M. I., Shaimaa Hasan, A., Tag-Adeen, M., Urata, Y., Goto, S., Luo, L., Yan, C. & Tao-Sheng, L. (2019). Immunomodulatory effect of mesenchymal stem cells: cell origin and cell quality variations. Molecular Biology Reports, 46(1), 1157-1165. https://doi.org/10.1007/s11033-018-04582-w
Fernández-Garza, L. E., Barrera-Barrera, S. A. & Barrera-Saldaña, H. A. (2023). Mesenchymal stem cell therapies approved by regulatory agencies around the world. Pharmaceuticals (Basel, Switzerland), 16(9), 1334. https://doi.org/10.3390/ph16091334
Harrell, C. R., Jankovic, M. G., Fellabaum, C., Volarevic, A., Djonov, V., Arsenijevic, A., & Volarevic, V. (2019). Molecular mechanisms responsible for anti-inflammatory and immunosuppressive effects of mesenchymal stem cell-derived factors. Advances in Experimental Medicine and Biology, 1084, 187-206. https://doi.org/10.1007/5584_2018_306
Hazrati, A., Mirarefin, S. M. J., Malekpour, K., Hazrati, A., Javad Mirarefin, S.M., Malekpour, K., Rahimi, A., Khosrojerdi, A., Rasouli, A., Akrami, S. & Soudi, S. (2024). Mesenchymal stem cell application in pulmonary disease treatment with emphasis on their interaction with lung-resident immune cells. Frontiers in Immunology, 15, 1469696. https://doi.org/10.3389/fimmu.2024.1469696
Huang, Y., Wu, Q., & Tam, P. K. H. (2022). Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. International Journal of Molecular Sciences, 23(17), 10023. https://doi.org/10.3390/ijms231710023
Kangari, P., Talaei-Khozani, T., Razeghian-Jahromi, I., & Razmkhah, M. (2020). Mesenchymal stem cells: Amazing remedies for bone and cartilage defects. Stem Cell Research & Therapy, 11(1), 492. https://doi.org/10.1186/s13287-020-02001-5
Krampera, M. & Le Blanc, K. (2021). Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell, 28(10), 1708-1725. https://doi.org/10.1016/j.stem.2021.09.006
Lim, R., Malhotra, A., Tan, J., & Mockler, J. C. (2018). Cell-based therapies for bronchopulmonary dysplasia: Future directions. Frontiers in Pediatrics, 6, 78. https://doi.org/10.3389/fped.2018.00078
O'Reilly, M., Möbius, M. A., Vadivel, A., Ionescu, L., Fung, M., Eaton, F., Greer, J.J., & Thébaud, B. (2020). Late rescue therapy with cord-derived mesenchymal stromal cells for established lung injury in experimental bronchopulmonary dysplasia. Stem Cells and Development, 29(6), 364-371. https://doi.org/10.1089/scd.2019.0116
Powell, S. B., & Silvestri, J. M. (2019). Safety of intratracheal administration of human umbilical cord blood-derived mesenchymal stromal cells in extremely low birth weight preterm infants. The Journal of Pediatrics, 210, 209-213.e2. https://doi.org/10.1016/j.jpeds.2019.02.029
Rawat, S., Gupta, S. & Mohanty, S. (2019). Mesenchymal stem cells modulate the immune system in developing therapeutic interventions. Immune Response Activation. IntechOpen. https://www.intechopen.com/chapters/65290
Tang, E., Zaidi, M., Wen‐Huey, L., Govindasamy, V., Kong-Yong, T., Khong-Lek, T., Kumar Das, A., & Soon-Keng, C. (2022). Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia. The Clinical Respiratory Journal, 16(10), 629-645. https://doi.org/10.1111/crj.13540
Tavakoli, S., Ghaderi Jafarbeigloo, H. R., Shariati, A., Jahangiryan, A., Jadidi, F., Jadidi Kouhbanani, M.A., Hassanzadeh, A., Zamani, M., Javidi, K., & Naimi, A. (2020). Mesenchymal stromal cells; a new horizon in regenerative medicine. Journal of Cellular Physiology, 235(12), 9185-9210. https://doi.org/10.1002/jcp.2980
Willis, G. R., Fernández-Gonzalez, A., Anastas, J., Vitali, S.H., Liu, X., Ericsson, M., Kwong, A., Mitsialis, S.A. & Kourembanas, A. (2018). Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. American Journal of Respiratory and Critical Care Medicine, 197(1), 104-116. https://doi.org/10.1164/rccm.201705-0925OC
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020). Mesenchymal stromal cell therapies: Immunomodulatory properties and clinical progress. Stem Cell Research & Therapy, 11(1), 345. https://doi.org/10.1186/s13287-020-01855-9
Yen, B. L., Liu, K. J., Sytwu, H. K., & Yen, M. L. (2023). Clinical implications of differential functional capacity between tissue-specific human mesenchymal stromal/stem cells. The FEBS Journal, 290(11), 2833-2844. https://doi.org/10.1111/febs.16438
You, J., Zhou, O., Liu, J., Zou, W., Zhang, L., Tian, D., Dai, J., Luo, Z., Liu, E., Fu, Z., & Zou, L. (2020). Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles alleviate lung injury in rat model of bronchopulmonary dysplasia by affecting cell survival and angiogenesis. Stem Cells and Development, 29(23), 1520-1532. https://doi.org/10.1089/scd.2020.0156
Zini, T., Miselli, F. & Berardi, A. (2023). Noninvasive Monitoring Strategies for Bronchopulmonary Dysplasia or Post-Prematurity Respiratory Disease: Current Challenges and Future Prospects. Children (Basel), 10(11), 1753. https://doi.org/10.3390/children10111753
